Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Retinoblastoma
Interventions
DRUG

3 cycles chemotherapy

Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.

DRUG

6 cycles chemotherapy

Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.

Trial Locations (1)

510000

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Sun Yat-sen University

OTHER

NCT01906814 - Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation | Biotech Hunter | Biotech Hunter